Amgen halts Vectibix combo trial
In an interim analysis of the study PACCE, Amgen finds that patients receiving Vectibix (panitumumab) combined with Genentech's Avastin (bevacizumab) and standard chemotherapy for treatment of first-line metastatic colorectal cancer had less chance of survival than patients receiving Avastin and chemotherapy alone. The EGFR inhibitor received accelerated approval on the basis of demonstrated improvement in progression-free survival in September, but failed to show an effect on overall survival. Amgen is continuing Phase III trials of Vectibix as a single agent in combination with chemotherapy...
You may also be interested in...
Join us for an audio catch-up on the latest key developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.